The POSEIDON program aims to create first-in-class synthetic sensor-based tests to detect over 30 cancers at Stage I using only non-invasive breath and urine samples.
Methylation profiling of cell-free DNA is opening new possibilities for detecting cancer at its earliest, pre-symptomatic stages, offering a potential breakthrough in how and when disease is found.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes.